Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Rapid Detection in Blood Cultures of ESBL-Producing Enterobacteriaceae

By LabMedica International staff writers
Posted on 04 Mar 2015
Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) technology has been used directly with blood cultures and was found to help guide clinical management of bacteremia caused by gram-negative bacteria (GNB).

Resistance to broad-spectrum cephalosporins is spreading rapidly among Enterobacteriaceae, mostly related to acquisition of extended-spectrum β-lactamases (ESBLs) and ESBL-producing Enterobacteriaceae (ESBL-E) are usually resistant to most β-lactams except cephamycins and carbapenems.

Microbiologist at the Institut National de la Santé et de la Recherche Médicale (Le Kremlin–Bicêtre, France) and their European colleagues studied a single blood culture positive for GNB from each of 245 hospitalized patients. More...
They performed antibiotic susceptibility testing (AST) by the disk diffusion method using bacterial colonies grown from blood cultures and used the double-disk synergy test (DDST) for the phenotypic detection of ESBL producers.

Positivity of blood cultures was detected by using the BacT/Alert system (bioMérieux; La Balme-les-Grottes, France). After obtaining Gram stain results, they tested the blood cultures positive for GNB directly for ESBL-E by using the ESBL Nordmann/Dortet/Poirel (NDP) test and species identification by using the bioMérieux Vitek MS MALDI-TOF MS technique. They also used molecular biology techniques to identify the ESBL genes using polymerase chain reaction (PCR) to amplify the DNA.

The 245 cases of bacteremia were attributed to Enterobacteriaceae (86.1%), nonfermentative GNB (12.7%), and anaerobic GNB (1.2%). Escherichia coli was the predominant enterobacterial species (55.9%); the next most prevalent were Klebsiella pneumoniae (17.5%) and Enterobacter cloacae (9.5%). Pseudomonas aeruginosa (24/31, 77.4%) was the predominant non-fermentative GNB. Anaerobic GNB belonged to the Bacteroides fragilis group (Bacillus fragilis and B. vulgatus). The team identified bacteria directly from blood culture using the MALDI-TOF technique for 237 (96.7%) isolates and the results corresponded to bacterial identification after culture.

The authors concluded that the ESBL NDP test directly performed on positive blood cultures is a reliable technique to identify ESBL-E within 30 minutes. A strong correlation between intermediate susceptibility or resistance to cefotaxime and positivity of the ESBL NDP test was observed. The inexpensive ESBL NDP test might be implemented worldwide. It may optimize rapid choices of antibiotics for treating bloodstream infections. It may also contribute to avoidance of overuse of carbapenems. Finally, a rapid detection of ESBL-E coupled with bacterial species identification will enhance identification of ESBL in species likely to be the source of nosocomial outbreak and facilitate implementation of a rapid strategy for containment. The study was published in the March 2015 issue of the journal Emerging Infectious Diseases.

Related Links:

Institut National de la Santé et de la Recherche Médicale 
bioMérieux



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.